163 related articles for article (PubMed ID: 22672386)
1. Expression of proto-oncogene KIT is up-regulated in subset of human meningiomas.
Saini M; Jha AN; Abrari A; Ali S
BMC Cancer; 2012 Jun; 12():212. PubMed ID: 22672386
[TBL] [Abstract][Full Text] [Related]
2. A subset of human gliomas shows over-expression of KIT without its amplification.
Saini M; Jha AN; Abrari A; Ali S
Gene; 2012 Apr; 497(2):155-63. PubMed ID: 22330882
[TBL] [Abstract][Full Text] [Related]
3. KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.
Chen EC; Karl TA; Kalisky T; Gupta SK; O'Brien CA; Longacre TA; van de Rijn M; Quake SR; Clarke MF; Rothenberg ME
Gastroenterology; 2015 Sep; 149(3):705-17.e2. PubMed ID: 26026391
[TBL] [Abstract][Full Text] [Related]
4. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
Nassehi D
Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
[TBL] [Abstract][Full Text] [Related]
5. Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
Fukami S; Riemenschneider MJ; Kohno M; Steiger HJ
Brain Tumor Pathol; 2016 Jul; 33(3):191-9. PubMed ID: 26942600
[TBL] [Abstract][Full Text] [Related]
6. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
[TBL] [Abstract][Full Text] [Related]
7. BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region.
Wozniak K; Piaskowski S; Gresner SM; Golanska E; Bieniek E; Bigoszewska K; Sikorska B; Szybka M; Kulczycka-Wojdala D; Zakrzewska M; Zawlik I; Papierz W; Stawski R; Jaskolski DJ; Och W; Sieruta M; Liberski PP; Rieske P
Cancer Genet Cytogenet; 2008 May; 183(1):14-20. PubMed ID: 18474292
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
9. Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas.
Sofela AA; Hilton DA; Ammoun S; Baiz D; Adams CL; Ercolano E; Jenkinson MD; Kurian KM; Teo M; Whitfield PC; Sahm F; Hanemann CO
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429944
[TBL] [Abstract][Full Text] [Related]
10. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
11. Correlation of proto-oncogene expression and proliferation and meningiomas.
Detta A; Kenny BG; Smith C; Logan A; Hitchcock E
Neurosurgery; 1993 Dec; 33(6):1065-74. PubMed ID: 8133992
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?
Sayagués JM; Tabernero MD; Maíllo A; Espinosa A; Rasillo A; Díaz P; Ciudad J; López A; Merino M; Gonçalves JM; Santos-Briz A; Morales F; Orfao A
J Mol Diagn; 2004 Nov; 6(4):316-25. PubMed ID: 15507670
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway.
Johnson MD; O'Connell MJ; Pilcher W; Reeder JE
J Neurosurg; 2010 May; 112(5):934-9. PubMed ID: 19698046
[TBL] [Abstract][Full Text] [Related]
14. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
15. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
16. Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningiomas.
Nagashima G; Aoyagi M; Yamamoto S; Wakimoto H; Tamaki M; Yamamoto K; Fujimoto T; Hirakawa K
Clin Neurol Neurosurg; 2001 Apr; 103(1):13-8. PubMed ID: 11311470
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
[TBL] [Abstract][Full Text] [Related]
18. The expression of disabled-2 is common reduced in meningiomas.
Zhang Z; Chen Y; Xie X; Tang J
Neurol India; 2014; 62(1):57-61. PubMed ID: 24608456
[TBL] [Abstract][Full Text] [Related]
19. Bcl2 and ROS1 expression in human meningiomas: an analysis with respect to histological subtype.
Girish V; Sachdeva N; Minz RW; Radotra B; Mathuria SN; Arora SK
Indian J Pathol Microbiol; 2005 Jul; 48(3):325-30. PubMed ID: 16761743
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
